title: Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology.
abstract: OBJECTIVE
  We evaluate the detection rate of insignificant prostate cancer and the rate of significant prostate cancer overlooked in the results of systematic sextant biopsy and fine needle aspiration biopsy of the prostate of asymptomatic men with serum prostate specific antigen concentrations less than 4.0 ng./ml.
  
  
  METHODS
  We analyzed specimens from 133 consecutive patients with a mean age of 60 years undergoing cystoprostatectomy for bladder cancer. Six systematic biopsy specimens and 2 fine needle aspiration cytology samples were taken from the prostate immediately after cystoprostatectomy. The specimens were step sectioned and examined for prostate cancer. Insignificant prostate cancer was defined as any cancer with an aggregate volume 0.5 cm.3 or less.
  
  
  RESULTS
  Incidental prostate cancer was found in 58 of the 133 patients (44%). Tumor volume was 0.5 cm.3 or less in 47 cases. Sextant biopsy detected 7 cancers, including 4 of 47 (9%) that were insignificant and 3 of 11 (27%) that were significant. Fine needle aspiration cytology also detected 7 cancers, including 3 (6%) and 4 (36%) that were insignificant and significant, respectively.
  
  
  CONCLUSIONS
  Systematic sextant biopsy and fine needle aspiration cytology each diagnose prostate cancer in about 5% of asymptomatic men who have normal digital rectal examination and serum prostate specific antigen less than 4.0 ng./ml. However, many of the cancers thus detected are insignificant and most of the significant cancers are missed. Therefore, routine screening of such patients with sextant biopsy or aspiration cytology does not appear to be justified.
authors.affiliation: Department of Urology, Institute of Pathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
authors.forename: S H
authors.initials: SH
authors.lastname: Hautmann
authors.forename: S
authors.initials: S
authors.lastname: Conrad
authors.forename: R P
authors.initials: RP
authors.lastname: Henke
authors.forename: A
authors.initials: A
authors.lastname: Erbersdobler
authors.forename: J
authors.initials: J
authors.lastname: Simon
authors.forename: M
authors.initials: M
authors.lastname: Straub
authors.forename: M
authors.initials: M
authors.lastname: Graefen
authors.forename: R E
authors.initials: RE
authors.lastname: Hautmann
authors.forename: H
authors.initials: H
authors.lastname: Huland
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D001707:Biopsy, Needle; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000517:prevention & control / Q000601:surgery; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen